AC IMMUNE SA (ACIU)
CH0329023102 - Common Stock
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
ACIU stock results show that AC Immune beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AC Immune (NASDAQ:ACIU) just reported results for the fourth quarter of 2023.AC...
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in...
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
Investors Snatch ACIU Even Lower Than Its Secondary Stock Offering
AC Immune stock slips as Roche ends Alzheimer’s deal (NASDAQ:ACIU)
AC Immune (ACIU) stock slips as Roche (RHHBY) ends collaboration agreements for Alzheimer's disease candidates, crenezumab and semorinemab. Read more here.
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active...
AC Immune issues updates on Phase 2 studies, cash runway (NASDAQ:ACIU)
AC Immune (ACIU) issued an update on its Phase 2 drug candidates for the treatment of Alzheimer’s and Parkinson diseases and said it has extended its cash runway into 2026.
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060...
AC Immune Alzheimer's drug advanced into Phase 2b testing (NASDAQ:ACIU)
AC Immune (ACIU) said that development partner Johnson & Johnson has advanced its Alzheimer's disease drug candidate into Phase 2b testing. Read more here.
AC Immune prices its 14.3M shares offering (NASDAQ:ACIU)
AC Immune pricing underwritten offering of 14.3M shares at $3.50 per share, expecting gross proceeds of ~$50.1M.
AC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the...
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b...
AC Immune makes interim CFO Christopher Roberts permanent (NASDAQ:ACIU)
AC Immune strengthens management by appointing Dr. Madiha Derouazi as CSO and Christopher Roberts as CFO.
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha...
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
Although growth penny stocks present extraordinary risks, if you exercise meticulous care, these ideas might be worth a shot.
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6...
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne,...
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
PRESS RELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative...
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a...
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a...
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC...
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060...
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA (NASDAQ: ACIU), a...